Core technology and international talent team

Slide Down

At present, the company is working on nearly 10 new R&D projects, mostly are extended/controlled-release products.Honglin pharmaceutical company owns 5 Chinese patents for its controlled-release technologies. The company also possesses sophisticated production equipment, such as imported laser drilling machine and many other advanced machines imported from the United States and Germany. Honglin pharmaceutical product line includes a variety fields of medications such as cardiovascular, endocrine, digestive, anti-allergenic, psychiatric, cold and analgesics. JUPOPINE^® (Nifedipine Controlled-release Tablets), RoToFier^® (Glipizide Extended Release Tablet), JUPOSHU^® (Amlodipine Besylate Tablets), and JUPOPHON^® (Ibuprofen Sustained-release Capsules) have passed the consistency evaluation.Our company pays attention to the introduction and training of talents. At present, there are several senior technical support personnel, doctors, masters, licensed pharmacists, etc., and technical support from the American expert management team.

Honglin Pharmaceutical inherits the legacy of osmotic pump controlled release formulations from ALZA Corporation, the pioneer of this technology in the United States. The company was gifted the first fully automatic mechanical drilling machine used for controlled-release tablet trials and has since collaborated in driving technological innovation. Through three generations of technological upgrades, Honglin has established a proprietary controlled release technology platform supported by independently developed patents.

Note: There are 5 controlled release technology patents in China, and the patent numbers (patent types) are
ZL200610153091.8 (invention patent),
ZL200710177989.3 (invention patent),
ZL200610113725.7 (invention patent),
ZL200610113984.X (invention patent),
and ZL200610114125.2 (invention patent).